Amarin Corp. PLC, the Irish heart-drug developer with a research base in Stonington, won two more patents covering intellectual property contained in its proprietary synthetic fish-oil pill.
The U.S. Patent and Trademark Office has published Notices of Allowance for Amarin’s U.S. patent applications, with serial numbers 13/458,496 and 13/349,157.
Obtaining all necessary patents and other protections are vital to Amarin bringing to global market its Vascepa drug that replicates beneficial omega-3 fatty acids for reducing blood triglycerides that can clog cardiovascular systems.
Amarin says it now has 15 U.S. patents either issued or allowed and is pursing more than 30 more.
